2015 Small-Cap Biotech Watchlist Announced
Interview

Release of The Life Sciences Report's 2015 Small-Cap Biotech Watchlist marks the third year we have brought together a team of analysts at the Biotech Showcase to compile a basket of stocks based on catalyst prospects for the coming year. This year's experts are some of the leading stock watchers in the space: Mara Goldstein, managing director and senior healthcare analyst at Cantor Fitzgerald; Reni Benjamin, head of equity research and senior healthcare analyst at H.C. Wainwright & Co.; Joe Pantginis, head of biotechnology research and senior research analyst at ROTH Capital Partners; and George Zavoico, managing director of equity research at MLV & Co. The companies in the Watchlist are poised for transformational events, which readers can monitor year-round in real time using the Portfolio Tracker.

Biotech Showcase attendees can hear the analysts' thoughts on the Watchlist companies at an exclusive panel discussion on Jan. 13, or sign up below to receive a summary of the conversation and updates on company progress throughout the year.

And the companies are:

The Life Sciences Report

SMALL-CAP BIOTECH WATCHLIST 2015

Logo	Company	Market Cap	Analyst	Therapy Area / Product
	Applied Genetic Technologies Corp.* (AGTC:NASDAQ)	$348M	Mara Goldstein, Cantor Fitzgerald	Genetic therapies for rare diseases including X-linked juvenile retinoschisis, achromatopsia and alpha-1 antitrypsin deficiency
	Can-Fite BioPharma Ltd.* (CANF:NASDAQ)	$34M	Reni Benjamin, H.C. Wainwright & Co.	Synthetic, specific agonists targeting the A3 adenosine receptor, including CF101, an oral drug in development for rheumatoid arthritis and psoriasis
	Lion Biotechnologies Inc.* (LBIO:NASDAQ)	$163M	Joe Pantginis, Roth Capital Partners	TIL Technology (tumor infiltrating lymphocytes); immunotherapeutic treatments targeting metastatic melanoma and solid tumors
	MEI Pharma Inc.* (MEIP:NASDAQ)	$129M	Joe Pantginis, Roth Capital Partners	Cancer treatment through inhibitors including pracinostat (hematological cancers), ME-344 and PWT143
	Oncothyreon Inc.* (ONTY:NASDAQ)	$160M	Reni Benjamin, H.C. Wainwright & Co.	Cancer therapies using small molecules and immunotherapies, including tecemotide, ONT-380 and ONT-10
	OncoSec Medical Inc.* (ONCS:NASDAQ)	$110M	Reni Benjamin, H.C. Wainwright & Co.	Electroporation platform technologies targeting skin cancers, including the OncoSec Medical System (OMS) and ImmunoPulse
	Peregrine Pharmaceuticals Inc.* (PPHM:NASDAQ)	$226M	George Zavoico, MLV & Co.	Treatment of cancer using monoclonal antibodies, including bavituximab, and the Tumor Necrosis Therapy (TNT) platform
	Sunesis Pharmaceuticals Inc.* (SNSS:NASDAQ)	$143M	Mara Goldstein, Cantor Fitzgerald	Cancer therapies targeting solid tumors and blood cancers including Qinprezo (vosaroxin)
	Synta Pharmaceuticals Inc.* (SNTA:NASDAQ)	$329M	George Zavoico, MLV & Co.	Inhibition of molecular chaperones in cancer, including ganetespib
	TG Therapeutics Inc.* (TGTX:NASDAQ)	$615M	Joe Pantginis, Roth Capital Partners	Cancer treatments using monoclonal antibodies and checkpoint inhibitors, including TGR-1101 (ublituximab) and TGR-1202
	Threshold Pharmaceuticals Inc. (THLD:NASDAQ)	$203M	George Zavoico, MLV & Co.	Induction of hypoxia in a variety of solid tumors and hematological cancers; lead compound is TH-302
	Verastem Inc.* (TSTM:NASDAQ)	$237M	Mara Goldstein, Cantor Fitzgerald	Inhibition of cancer stem cell pathways; compounds include VS-6063 (mesothelioma, lung and ovarian cancer)
Information in this chart was pulled from company websites and Yahoo Finance. Companies with an * are not affiliated with Streetwise Reports.

Dr. Reni Benjamin is a managing director and equity research analyst at H.C. Wainwright & Co. His expertise and coverage focuses on companies in the oncology and stem cell sectors. Benjamin has been ranked among the top analysts for recommendation performance and earnings accuracy by StarMine, has been cited in a variety of sources including The Wall Street Journal, Bloomberg Businessweek, Financial Times and Smart Money, and has made appearances on Bloomberg television/radio and CNBC. He authored a chapter in "The Delivery of Regenerative Medicines and Their Impact on Healthcare," has presented at various regional and international conferences, and has been published in peer-reviewed journals. He currently serves on the UAB School of Health Professions' Deans Advisory Board. Prior to joining H.C. Wainwright, Benjamin was a managing director and senior biotechnology analyst at both Burrill Securities and Rodman & Renshaw. He was also an associate analyst at Needham and Company. Benjamin earned his doctorate from the University of Alabama at Birmingham in biochemistry and molecular genetics by discovering and characterizing a novel gene implicated in germ cell development. He earned a bachelor's degree in biology from Allegheny College.

Mara Goldstein joined Cantor Fitzgerald & Co. from Thomson Reuters, where she served as director of research for Reuters Insight. Goldstein was initially responsible for the firm's healthcare research practice, and later assumed responsibility for all research activities and sectors. Prior to that, Goldstein was an executive director and senior pharmaceutical analyst at CIBC World Markets. At Cantor, Goldstein covers the biotechnology sector. Goldstein also worked at Alex Brown & Sons and CS First Boston. She holds a bachelor's degree in economics from Purdue University.

Joseph Pantginis, Ph.D., joined ROTH Capital Partners in 2009. Prior to joining ROTH, Pantginis was a senior biotech analyst at Merriman Curhan Ford (now Merriman Holdings Inc.). Pantginis was also a senior biotechnology analyst at Canaccord Adams, focusing on the oncology, inflammation and infectious disease spaces. Prior to Canaccord Adams he was a biotech analyst at several firms, including JbHanauer & Co., First Albany Corp., Commerce Capital Markets Inc. and Ladenburg Thalmann & Co. Inc. Prior to his tenure on Wall Street, Pantginis served as an associate manager/scientist of Regeneron Pharmaceuticals' Retrovirus Core Facility. Pantginis received a master's degree in business administration (finance) from Pace University; a doctorate in molecular genetics and a master's degree from Albert Einstein College of Medicine; and a bachelor's degree from Fordham University.

Dr. George Zavoico, managing director and senior equity analyst at MLV & Co., has more than 10 years of experience as a life sciences equity analyst writing research on publicly traded equities. His principal focus is on biotechnology, biopharmaceutical, specialty pharmaceutical, and molecular diagnostics companies. He received The Financial Times/Starmine Award two years in a row for being among the top-ranked earnings estimators in the biotechnology sector. Previously, Zavoico was an equity research analyst in the healthcare sector at Westport Capital Markets and Cantor Fitzgerald. Prior to working as an analyst, Zavoico established his own consulting company serving the biotech and pharmaceutical industries, providing competitive intelligence and marketing research, due diligence services and guidance in regulatory affairs. Zavoico began his career as a senior research scientist at Bristol-Myers Squibb Co., moving on to management positions at Alexion Pharmaceuticals Inc. and T Cell Sciences Inc. (now Celldex Therapeutics Inc.). Zavoico has a bachelor's degree in biology from St. Lawrence University and a Ph.D. in physiology from the University of Virginia. He held post-doctoral fellowships at the University of Connecticut School of Medicine and Harvard Medical School/Brigham & Women's Hospital. He has published more than 30 papers in peer-reviewed journals and has coauthored four book chapters.

DISCLOSURE:
1) JT Long and Tracy Salcedo-Chourre prepared this article for Streetwise Reports LLC, publisher of The Gold Report, The Energy Report, The Life Sciences Report and The Mining Report, and provide services to Streetwise Reports as employees. They own, or their families own, shares of the following companies mentioned in this interview: None.
2) The following companies mentioned in the interview are sponsors of Streetwise Reports: Threshold Pharmaceuticals Inc. The companies mentioned in this interview were not involved in any aspect of the interview preparation or post-interview editing so the expert could speak independently about the sector. Streetwise Reports does not accept stock in exchange for its services.
3) Reni Benjamin: I own, or my family owns, shares of the following companies mentioned in this interview: None. I personally am, or my family is, paid by the following companies mentioned in this interview: None. My company has a financial relationship with the following companies mentioned in this interview: Can-Fite BioPharma, Oncothyreon, and OncoSec Medical. I was not paid by Streetwise Reports for participating in this interview. Comments and opinions expressed are my own comments and opinions. I determined and had final say over which companies would be included in the interview based on my research, understanding of the sector and interview theme. I had the opportunity to review the interview for accuracy as of the date of the interview and am responsible for the content of the interview.
4) Mara Goldstein: For important disclosures on companies mentioned, please go to www.cantor.com/futuresdisclosures.
5) Joseph Pantginis: I own, or my family owns, shares of the following companies mentioned in this interview: None. I personally am, or my family is, paid by the following companies mentioned in this interview: None. My company has a financial relationship with the following companies mentioned in this interview: Lion Biotechnologies, MEI Pharma, TG Therapeutics. I was not paid by Streetwise Reports for participating in this interview. Comments and opinions expressed are my own comments and opinions. I determined and had final say over which companies would be included in the interview based on my research, understanding of the sector and interview theme. I had the opportunity to review the interview for accuracy as of the date of the interview and am responsible for the content of the interview.
6) George Zavoico: I own, or my family owns, shares of the following companies mentioned in this interview: None. I personally am, or my family is, paid by the following companies mentioned in this interview: None. My company has a financial relationship with the following companies mentioned in this interview: Peregrine Pharmaceuticals, Synta Pharmaceuticals, Threshold Pharmaceuticals. I was not paid by Streetwise Reports for participating in this interview. Comments and opinions expressed are my own comments and opinions. I determined and had final say over which companies would be included in the interview based on my research, understanding of the sector and interview theme. I had the opportunity to review the interview for accuracy as of the date of the interview and am responsible for the content of the interview.
7) Interviews are edited for clarity. Streetwise Reports does not make editorial comments or change experts' statements without their consent.
8) The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer.
9) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their families are prohibited from making purchases and/or sales of those securities in the open market or otherwise during the up-to-four-week interval from the time of the interview until after it publishes.